INTELLIA THERAPEUTICS INC. - COMMON STOCK

21.57

19-April-24 15:59:59

15 minutes delayed

Stocks

+0.25

+1.17%

Today's range

20.78 - 21.63

ISIN

N/A

Source

NASDAQ

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

23 Oct 2023 09:45:06 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

20 Oct 2023 15:35:16 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

19 Oct 2023 11:03:11 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

18 Oct 2023 09:47:49 By NetDania Notify
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

18 Oct 2023 07:00:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

13 Oct 2023 08:38:43 By Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 Oct 2023 10:22:49 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

03 Oct 2023 09:46:00 By NetDania Notify
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 Oct 2023 09:47:30 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

28 Sep 2023 10:40:05 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

27 Sep 2023 12:37:57 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

25 Sep 2023 09:45:02 By NetDania Notify
NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

22 Sep 2023 16:02:18 By NetDania Notify
Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

03 Aug 2023 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

27 Jul 2023 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

11 Jun 2023 08:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

05 Jun 2023 16:01:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

31 May 2023 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

04 May 2023 07:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.